Aquatic Capital Management LLC Purchases Shares of 1,674 Ascendis Pharma A/S (NASDAQ:ASND)

Aquatic Capital Management LLC purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,674 shares of the biotechnology company's stock, valued at approximately $230,000.

A number of other large investors also recently modified their holdings of ASND. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $30,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Ascendis Pharma A/S by 195.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 664 shares during the last quarter.

Ascendis Pharma A/S Trading Down 4.8 %

Ascendis Pharma A/S stock traded down $8.27 during trading hours on Tuesday, reaching $162.47. 825,110 shares of the company were exchanged, compared to its average volume of 496,236. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The stock has a 50-day moving average of $155.86 and a 200 day moving average of $140.86. The firm has a market cap of $9.91 billion, a price-to-earnings ratio of -22.88 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. As a group, research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday. Royal Bank of Canada raised their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday. UBS Group began coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price on the stock. Cantor Fitzgerald increased their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 25th. Finally, Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research report on Friday. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average target price of $216.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.